该项收购完成后,Cambrex公司将获得Avista公司包括从原料药、药品开发、环化核苷酸制造,到独立分析、微生物测验以及固态科学等多项服务,同时将Avista的4个制药站点纳入其生...查看全文
琬麟2015-02-07 09:21
$凯姆布雷克斯(CBM)$ EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continu...查看全文
$凯姆布雷克斯(CBM)$ DEF 14A - Other definitive proxy statements Filed: 2019-03-12 AccNo: 0001564590-19-007364 Size: 1 MB 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-03-12 AccNo: 0001564590-19-007375 Size: 182 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K/A [Amend] - Current report Filed: 2019-03-11 AccNo: 0001193125-19-069418 Size: 669 KBItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 内部交易: 2019-02-15,EVP & COO,Cavanagh Shawn ,卖出,6769普通股, $37.60
$凯姆布雷克斯(CBM)$ 内部交易: 2019-02-15,CFO & EVP, Corp. Dev.,SARGEN GREGORY ,卖出,5802普通股, $37.45
$凯姆布雷克斯(CBM)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-13 AccNo: 0001144204-19-007189 Size: 54 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-02-13 AccNo: 0001564590-19-002749 Size: 2 MBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-02-13 AccNo: 0001564590-19-002751 Size: 18 MB 网页链接
$凯姆布雷克斯(CBM)$ 美东时间 2019-02-13 盘前 披露财报,预期EPS 1.32 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-02-06 AccNo: 0001564590-19-002167 Size: 105 KBItem 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 9.01: Financial Statements and Exhibits 网页链接